Novartis AG ADR (NVS) News

Novartis AG ADR (NVS): $105.55

1.04 (+1.00%)

POWR Rating

Component Grades

Momentum

C

Stability

B

Sentiment

Quality

B

Add NVS to Watchlist
Sign Up

Filter NVS News Items

NVS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVS News Highlights

  • For NVS, its 30 day story count is now at 18.
  • Over the past 28 days, the trend for NVS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about NVS are DRUG, III and MS.

Latest NVS News From Around the Web

Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Why Is Cytokinetics (CYTK) Stock Up 70% Today?

With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.

Josh Enomoto on InvestorPlace | December 27, 2023

Novartis (NVS) Outperforms Broader Market: What You Need to Know

Novartis (NVS) closed at $99.71 in the latest trading session, marking a +1.18% move from the prior day.

Yahoo | December 27, 2023

The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours

Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours are part of the Zacks top Analyst Blog.

Yahoo | December 26, 2023

Novartis (NVS) Stock Moves -1.17%: What You Should Know

Novartis (NVS) closed the most recent trading day at $97.14, moving -1.17% from the previous trading session.

Yahoo | December 20, 2023

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

Yahoo | December 20, 2023

Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

Yahoo | December 19, 2023

Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?

The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now.

Rich Duprey on InvestorPlace | December 17, 2023

Amgen finds a new top scientist in Novartis veteran Bradner

Jay Bradner, a well-known physician-scientist who left Novartis last year amid an organizational shakeup, will now serve a Amgen’s chief scientific officer and head of R&D.

Yahoo | December 15, 2023

Novartis (NVS) Stock Sinks As Market Gains: Here's Why

In the most recent trading session, Novartis (NVS) closed at $98.87, indicating a -0.84% shift from the previous trading day.

Yahoo | December 14, 2023

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying ca

Yahoo | December 11, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!